不同病程的结核病患者的血浆代谢组学研究
收稿日期: 2016-01-04
修回日期: 2016-04-08
网络出版日期: 2016-06-05
基金资助
国家科技重大专项资助项目(2013ZX10003002-006).
Plasma Metabonomics in Tuberculosis Patients at Different Stages
Received date: 2016-01-04
Revised date: 2016-04-08
Online published: 2016-06-05
结核病(tuberculosis, TB)是第二大由单一病原菌感染引起的致死性疾病,致死率仅次于艾滋病.与疾病进展相关的代谢标志物的发现有利于病情的防治,而代谢组学研究则是发现代谢标志物的重要手段之一.目前与TB病人相关的代谢组学研究还不多.该文利用基于核磁共振氢谱(1H NMR)的代谢组学技术,对不同病情程度TB患者的血浆代谢组进行了研究.正交偏最小二乘法判别分析(OPLS-DA)结果显示TB各组与健康对照组均可明显分离.统计分析发现,缬氨酸、丙氨酸、肌酸和3-羟基丁酸等代谢物在TB各组含量普遍高于对照组;乳酸、丙酮酸、N-乙酰糖蛋白、亮氨酸和谷氨酸等代谢物在疾病进展过程中呈逐渐增加的趋势,而三羧酸(tricartexylic acid, TCA)循环的中间产物——柠檬酸则呈逐渐降低的趋势,表明了代谢紊乱随疾病的逐渐变化过程.这些差异代谢物的变化表明TB患者体内能量代谢与糖酵解增强、脂肪酸生酮作用增强、TCA循环受阻、氨基酸代谢紊乱.
关键词： 核磁共振(NMR); 代谢组学; 正交偏最小二乘法判别分析(OPLS-DA); 结核病; 差异代谢物
许怡 , 孙博 , 张琪 , 戴二黑 , 颜贤忠 , 董方霆 , 周宁 , 杜祥博 , 杨莉 . 不同病程的结核病患者的血浆代谢组学研究[J]. 波谱学杂志, 2016 , 33(2) : 224 -235 . DOI: 10.11938/cjmr20160205
Tuberculosis (TB) is the second largest infectious disease caused by a single pathogen leading to mortality, only after AIDS. Discovery of biomarkers associated with disease progression is vital for TB screening and control. Metabonomics is among the most useful tools for this purpose. A few metabonomic studies on TB patients have been published. In this study, the plasma samples of TB patients with varying severity were studied by 1H NMR based metabonomics. Orthogonal partial least squares-discriminant analysis (OPLS-DA) models showed that TB patients at different stages and healthy controls could be differentiated by their plasma metabolic profiles. It was found that the TB groups had significantly higher levels of valine, alanine, creatine, and 3-hydroxybutyrate, relative to the healthy controls. In the TB patients, the levels of lactate, pyruvate, N-acetyl glycoprotein, leucine and glutamate increased gradually with disease progression, while the level of citrate, a tricarboxylic acid (TCA) cycle intermediate, decreased with disease progression. The plasma metabolic profile changes indicated increased energy metabolism and glycolysis, enhanced ketogenesis of fatty acid, reduced TCA cycle, and disordered amino acid metabolism in the TB patients.
Key words： NMR; metabonomics; OPLS-DA; tuberculosis; differential metabolites
[1] Lawn S D, Zumla A I. Tuberculosis[J]. Lancet, 2011, 378(9785):57-72.
[2] McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers:Needs, challenges, recent advances, and opportunities[J]. J Infect Dis, 2012, 205(Suppl 2):S147-S158.
[3] Dowdy D W, Steingart K F, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in India:A cost-effectiveness analysis[J]. PLoS Med, 2011, 8(8):e1001074.
[4] Pai M, Zwerling A, Menzies D. Systematic review:T-cell-based assays for the diagnosis of latent tuberculosis infection:an update[J]. Ann Intern Med, 2008, 149(3):177-184.
[5] Brosch R, Vincent V. Cutting-edge science and the future of tuberculosis control[J]. Bull World Health Organ, 2007, 85(5):410-412.
[6] Katoch V M. Newer diagnostic techniques for tuberculosis[J]. Indian J Med Res, 2004, 120(4):418-428.
[7] Cole S T, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence[J]. Nature, 1998, 393(6685):537-544.
[8] Zhang J, Wu X F, Shi L L, et al. Diagnostic serum proteomic analysis in patients with active tuberculosis[J]. Clin Chim Acta, 2012, 413(9, 10):883-887.
[9] Xu D D, Deng D F, Li X, et al. Discovery and identification of serum potential biomarkers for pulmonary tuberculosis using iTRAQ-coupled two-dimensional LC-MS/MS[J]. Proteomics, 2014, 14(2, 3):322-331.
[10] Zhang C, Song X, Zhao Y, et al. Mycobacterium tuberculosis secreted proteins as potential biomarkers for the diagnosis of active tuberculosis and latent tuberculosis infection[J]. J Clin Lab Anal, 2015, 29(5):375-382.
[11] German J B, Bauman D E, Burrin D G, et al. Metabolomics in the opening decade of the 21st century:Building the roads to individualized health[J]. J Nutr, 2004, 134(10):2729-2732.
[12] Shin J H, Yang J Y, Jeon B Y, et al. 1H-NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis[J]. J Proteome Res, 2011, 10(5):2238-2247.
[13] Somashekar B S, Amin A G, Rithner C D, et al. Metabolic profiling of lung granuloma in Mycobacterium tuberculosis infected guinea pigs:ex vivo 1H magic angle spinning NMR studies[J]. J Proteome Res, 2011, 10(9):4186-4195.
[14] Somashekar B S, Amin A G, Tripathi P, et al. Metabolomic signatures in guinea pigs infected with epidemic-associated W-Beijing strains of Mycobacterium tuberculosis[J]. J Proteome Res, 2012, 11(10):4873-4884.
[15] Chen Y, Wu J, Tu L, et al. 1H NMR spectroscopy revealed Mycobacterium tuberculosis caused abnormal serum metabolic profile of cattle[J]. PLoS One, 2013, 8(9):e74507.
[16] Baughn A D, Rhee K Y. Metabolomics of central carbon metabolism in Mycobacterium tuberculosis[J]. Microbiol Spectr, 2014, 2(3):323-329.
[17] Nandakumar M, Prosser G A, de Carvalho L P, et al. Metabolomics of Mycobacterium tuberculosis[J]. Methods Mol Biol, 2015, 1285:105-115.
[18] Weiner J, Parida S K, Maertzdorf J, et al. Biomarkers of inflammation,immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients[J]. PLoS One, 2012, 7(7):e40221.
[19] du Preez I, Loots D T. New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa[J]. Tuberculosis (Edinb), 2013, 93(3):330-337.
[20] Che N, Cheng J, Li H, et al. Decreased serum 5-oxoproline in TB patients is associated with pathological damage of the lung[J]. Clin Chim Acta, 2013, 423(23):5-9.
[21] Zhou A, Ni J, Xu Z, et al. Application of 1H NMR spectroscopy-based metabolomics to sera of tuberculosis patients[J]. J Proteome Res, 2013, 12(10):4642-4649.
[22] Lau S K, Lee K C, Curreem S O, et al. Metabolomic profiling of plasma from patients with tuberculosis by use of untargeted mass spectrometry reveals novel biomarkers for diagnosis[J]. J Clin Microbiol, 2015, 53(12):3750-3759.
[23] Zhang He-qiu(张贺秋), Zhao Yan-lin(赵雁林). Modern Tuberculosis Diagnosis Techniques(现代结核病诊断技术)[M]. Beijing(北京):People's Medical PublishingHouse(人民卫生出版社), 2013.
[24] Savorani F, Tomasi G, Engelsen S B. Icoshift:A versatile tool for the rapid alignment of 1D NMR spectra[J]. J Magn Reson, 2010, 202:190-202.
[25] Chen Lu(陈璐), Song Kan(宋侃), Wang Yu-lan(王玉兰). Effects of attenuated salmonella typhimurium infection on fecal metabonome in mice (感染减毒鼠伤寒沙门氏菌对小鼠粪样代谢组的影响)[J]. Chinese J Magn Reson(波谱学杂志), 2014, 31(3):349-363.
[26] Jiang L M, Huang J, Wang Y L, et al. Metabonomic analysis reveals the CCl4-induced systems alterations for multiple rat organs[J]. J Proteome Res, 2012, 11(7):3848-3859.
[27] Eriksson L, Johansson E, Kettaneh-Wold N, et al. Multi- and Megavariate Data Analysis[M]. New York:MKS Umetrics AB, 2006.
[28] Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS® models[J]. J Chemometr, 2008, 22(11, 12):594-600.
[29] Wallimann T, Tokarska-Schlattner M, Schlattner U. The creatine kinase system and pleiotropic effects of creatine[J]. Amino Acids, 2011, 40(5):1271-1296.
[30] de Backer D. Lactic acidosis[J]. Intensive Care Med, 2003, 29(5):699-702.
[31] Sun L, Hu W, Liu Q, et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients[J]. J Proteome Res, 2012, 11(5):2937-2946.
[32] Macallan D C. Malnutrition in tuberculosis[J]. Diagn Microbiol Infect Dis, 1999, 34(2):153-157.
[33] Schwenk A, Macallan D C. Tuberculosis, malnutrition and wasting[J]. Curr Opin Clin Nutr Metab Care, 2000, 3(4):285-291.
[34] Macallan D C, McNurlan M A, Kurpad A V, et al. Whole body protein metabolism in human pulmonary tuberculosis and undernutrition:Evidence for anabolic block in tuberculosis[J]. Clin Sci (Lond), 1998, 94(3):321-331.
[35] Blumenthal A, Isovski F, Rhee K Y. Tuberculosis and host metabolism:ancient associations, fresh insights[J]. Transl Res, 2009, 154(1):7-14.
[36] Kinscherf R, Hack V, Fischbach T, et al. Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals:the effect of N-acetyl-cysteine[J]. J Mol Med (Berl), 1996, 74(7):393-400.
/
| 〈 |
|
〉 |